WO2009031826A1 - Process for preparing vitis vinifera pip extract and pharmaceutical composition for preventing or treating rheumatoid arthritis comprising the same - Google Patents
Process for preparing vitis vinifera pip extract and pharmaceutical composition for preventing or treating rheumatoid arthritis comprising the same Download PDFInfo
- Publication number
- WO2009031826A1 WO2009031826A1 PCT/KR2008/005203 KR2008005203W WO2009031826A1 WO 2009031826 A1 WO2009031826 A1 WO 2009031826A1 KR 2008005203 W KR2008005203 W KR 2008005203W WO 2009031826 A1 WO2009031826 A1 WO 2009031826A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- vitis vinifera
- resultant
- pharmaceutical composition
- drying
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 213
- 240000006365 Vitis vinifera Species 0.000 title claims abstract description 152
- 235000014787 Vitis vinifera Nutrition 0.000 title claims abstract description 152
- 235000002532 grape seed extract Nutrition 0.000 title claims abstract description 151
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 29
- 206010039073 rheumatoid arthritis Diseases 0.000 title claims abstract description 27
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 23
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 147
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 78
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 62
- 238000000605 extraction Methods 0.000 claims description 54
- 239000000706 filtrate Substances 0.000 claims description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 50
- 238000001914 filtration Methods 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 42
- 239000011780 sodium chloride Substances 0.000 claims description 42
- 230000008569 process Effects 0.000 claims description 37
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 24
- 238000001035 drying Methods 0.000 claims description 23
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- 239000012141 concentrate Substances 0.000 claims description 17
- 230000002829 reductive effect Effects 0.000 claims description 15
- 239000012046 mixed solvent Substances 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 14
- 238000004821 distillation Methods 0.000 claims description 13
- JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 claims description 12
- 229920001991 Proanthocyanidin Polymers 0.000 claims description 12
- 238000001694 spray drying Methods 0.000 claims description 12
- 229930013915 (+)-catechin Natural products 0.000 claims description 11
- 235000007219 (+)-catechin Nutrition 0.000 claims description 11
- 229930013783 (-)-epicatechin Natural products 0.000 claims description 11
- 235000007355 (-)-epicatechin Nutrition 0.000 claims description 11
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 5
- 230000001376 precipitating effect Effects 0.000 claims description 5
- 238000009738 saturating Methods 0.000 claims description 5
- 239000011259 mixed solution Substances 0.000 claims description 4
- 230000001976 improved effect Effects 0.000 abstract description 5
- 241001465754 Metazoa Species 0.000 description 58
- 208000009386 Experimental Arthritis Diseases 0.000 description 45
- 206010003246 arthritis Diseases 0.000 description 31
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- 238000012360 testing method Methods 0.000 description 24
- 239000000203 mixture Substances 0.000 description 21
- 239000012088 reference solution Substances 0.000 description 21
- 102000013691 Interleukin-17 Human genes 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- 230000003247 decreasing effect Effects 0.000 description 18
- 210000001744 T-lymphocyte Anatomy 0.000 description 17
- 239000007924 injection Substances 0.000 description 16
- 238000002347 injection Methods 0.000 description 16
- 239000012085 test solution Substances 0.000 description 16
- 230000001965 increasing effect Effects 0.000 description 14
- 239000012086 standard solution Substances 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 239000007928 intraperitoneal injection Substances 0.000 description 12
- 102000004127 Cytokines Human genes 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 235000008504 concentrate Nutrition 0.000 description 11
- 238000011156 evaluation Methods 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000002757 inflammatory effect Effects 0.000 description 9
- 239000003960 organic solvent Substances 0.000 description 9
- 108090000978 Interleukin-4 Proteins 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 238000010171 animal model Methods 0.000 description 8
- 238000007796 conventional method Methods 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 239000002158 endotoxin Substances 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 229920006008 lipopolysaccharide Polymers 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 102100040247 Tumor necrosis factor Human genes 0.000 description 7
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 7
- 229960000590 celecoxib Drugs 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000012535 impurity Substances 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 210000000845 cartilage Anatomy 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 102100022297 Integrin alpha-X Human genes 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 5
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 5
- 210000004443 dendritic cell Anatomy 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 229920002414 procyanidin Polymers 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 210000001541 thymus gland Anatomy 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 238000011088 calibration curve Methods 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 238000011109 contamination Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 102000054350 human CHI3L1 Human genes 0.000 description 4
- 210000001503 joint Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000003289 regulatory T cell Anatomy 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 3
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 3
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 210000000544 articulatio talocruralis Anatomy 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 3
- 229920002770 condensed tannin Polymers 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 description 2
- 240000007551 Boswellia serrata Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 241001111421 Pannus Species 0.000 description 2
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 210000000068 Th17 cell Anatomy 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 241000219094 Vitaceae Species 0.000 description 2
- 241000219095 Vitis Species 0.000 description 2
- 235000009392 Vitis Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000005067 joint tissue Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- SBZWTSHAFILOTE-SOUVJXGZSA-N (2R,3S,4S)-leucocyanidin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3[C@H](O)[C@@H]2O)=CC=C(O)C(O)=C1 SBZWTSHAFILOTE-SOUVJXGZSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- KZFDKINRISJFCO-UHFFFAOYSA-N 2-[(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)oxy-phenylmethyl]aniline Chemical compound CN1C(C2)CCC1CC2OC(C=1C(=CC=CC=1)N)C1=CC=CC=C1 KZFDKINRISJFCO-UHFFFAOYSA-N 0.000 description 1
- NBGQZFQREPIKMG-UHFFFAOYSA-N 3beta-hydroxy-beta-boswellic acid Natural products C1CC(O)C(C)(C(O)=O)C2CCC3(C)C4(C)CCC5(C)CCC(C)C(C)C5C4=CCC3C21C NBGQZFQREPIKMG-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010071155 Autoimmune arthritis Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 235000018062 Boswellia Nutrition 0.000 description 1
- 235000012035 Boswellia serrata Nutrition 0.000 description 1
- NBGQZFQREPIKMG-PONOSELZSA-N Boswellic acid Chemical compound C1C[C@@H](O)[C@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C NBGQZFQREPIKMG-PONOSELZSA-N 0.000 description 1
- 240000001548 Camellia japonica Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- UYUXSRADSPPKRZ-UHFFFAOYSA-N D-glucuronic acid gamma-lactone Natural products O=CC(O)C1OC(=O)C(O)C1O UYUXSRADSPPKRZ-UHFFFAOYSA-N 0.000 description 1
- UYUXSRADSPPKRZ-SKNVOMKLSA-N D-glucurono-6,3-lactone Chemical compound O=C[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@H]1O UYUXSRADSPPKRZ-SKNVOMKLSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241001289529 Fallopia multiflora Species 0.000 description 1
- OEIJRRGCTVHYTH-UHFFFAOYSA-N Favan-3-ol Chemical compound OC1CC2=CC=CC=C2OC1C1=CC=CC=C1 OEIJRRGCTVHYTH-UHFFFAOYSA-N 0.000 description 1
- CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 240000002924 Platycladus orientalis Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 241000220221 Rosales Species 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 241001299682 Salix purpurea Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010040954 Skin wrinkling Diseases 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000002503 Vitis amurensis Species 0.000 description 1
- 235000004283 Vitis amurensis Nutrition 0.000 description 1
- 240000000956 Vitis coignetiae Species 0.000 description 1
- 235000007068 Vitis coignetiae Nutrition 0.000 description 1
- 244000070384 Vitis labrusca Species 0.000 description 1
- 235000004282 Vitis labrusca Nutrition 0.000 description 1
- 240000003180 Vitis riparia Species 0.000 description 1
- 235000012124 Vitis riparia Nutrition 0.000 description 1
- 244000070471 Vitis rupestris Species 0.000 description 1
- 235000004284 Vitis rupestris Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 235000018597 common camellia Nutrition 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- -1 expander Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000011987 flavanols Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229950002441 glucurolactone Drugs 0.000 description 1
- 238000007825 histological assay Methods 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000037189 immune system physiology Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 210000001872 metatarsal bone Anatomy 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960001553 phloroglucinol Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000011764 rheumatoid arthritis animal model Methods 0.000 description 1
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 1
- CQRYARSYNCAZFO-UHFFFAOYSA-N salicyl alcohol Chemical compound OCC1=CC=CC=C1O CQRYARSYNCAZFO-UHFFFAOYSA-N 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- Korean Patent No. 10-0509119 discloses that a procyanidin oligomer (catechin ⁇ -phloroglucinol), obtained from Ulmi cortex using a mult-step extraction process including column chromatography, inhibits activity of matrix metalloproteinase (MMP), and thus can be efficiently used to prevent and treat diseases such as cancer migration, periodontal diseases, rheumatoid arthritis, inflammation, hyperparathyroidism, diabetes, corneal ulcer, osteoporosis, stomach ulcer, trauma, wrinkles, acne, AIDS, burn, arteriosclerosis, bone fracture.
- MMP matrix metalloproteinase
- the present inventors conducted research in order to develop an improved process for preparing a Vitis vinifera extract through a simple process.
- the present inventors have found that, by extracting Vitis vinifera seeds using a water-acetone mixture containing a relatively small amount of acetone as a first extraction solvent, removing acetone by distillation, and then directly treating the resultant aqueous layer with sodium chloride, the extraction can be performed at room temperature (at about 25 " C) and also distillation can be simplified.
- the extraction process can be simplified since it is not necessary to perform extraction step using a water-immiscible organic solvent.
- the volume ratio of acetone and water in the mixed solvent of step (a) may be 1 : 1.5.
- the extraction of steps (a) and (c) may be repeated 2 to 3 times.
- the distillation of step (b) may be conducted at 50 0 C or less under a reduced pressure and the filtering of step (b) may be conducted after standing for 2 to 3 hours from the saturation with sodium chloride.
- the concentrating in step (c) may be conducted to a volume of 0.4 to 0.7 times of the total volume of the extract.
- the obtained Vitis vinifera pip extract in the above processes have 80-130% of Procyanidolic value (PCV); 30% or less of (+)catechin and (-)epicatechin; and 95-105% of proanthocyanidin.
- a pharmaceutical composition for preventing or treating rheumatoid arthritis comprising a Vitis vinifera pip extract as an active ingredient and a pharmaceutically acceptable carrier.
- the Vitis vinifera pip extract is prepared in accordance with the above processes. More preferably, the Vitis vinifera pip extract has 80-130% of Procyanidolic value (PCV); 30% or less of (+)catechin and (-)epicatechin; and 95-105% of proanthocyanidin.
- FIG. 3 illustrates the degree of destruction of joints and cartilaginous tissues of CIA animals, CIA animals into which each of 50 mg/kg and 10 mg/kg of the Vitis vinifera pip extract is injected, and normal animals after sacrificing them, through tissue staining.
- FIG. 4 illustrates the amount of Type Il collagen-specific antibodies (anti-CII).
- FIG. 7 illustrates the degree of expression of IL-17 mRNA, using a real-time transcriptase-polymerase chain reaction (PCR), from draining lymph nodes (dLN) which are obtained from CIA animals into which 50 mg/kg and 10 mg/kg of Vitis vinifera pip extract or saline are respectively injected, and cultured in culture media unsupplemented or supplemented with 10 ⁇ g/ml of the Vitis vinifera pip extract with stimulation of anti-CD3, CII, and lipopolysaccharide (LPS) for 3 days.
- PCR real-time transcriptase-polymerase chain reaction
- the process of the present invention includes adding chloroform to the concentrate prepared in step (c), and then precipitating the resultant by filtration [step (d)].
- chloroform When chloroform is added to the concentrate, active ingredients including oligomers which are not dissolved in chloroform are precipitated.
- the Vitis vinifera pip extract may be simply isolated by filtering the precipitate.
- the precipitate prepared by the filtration may be dried using a conventional method to obtain dried powder. The drying may be conducted under a reduced pressure, for example, at 50 °C or less under a reduced pressure.
- the present invention also includes a process for preparing a Vitis vinifera pip extract, the process comprising: (A) preparing a first extract by (i) extracting pulverized seeds of Vitis vinifera with a mixed solvent of acetone and water in a volume ratio of 3-5 : 1 , and then filtering the resultant; (ii) concentrating the filtrate prepared in step (i) to remove acetone, and then filtering the resultant; (iii) extracting the filtrate prepared in step (ii) with ethyl acetate; and (iv) drying the extract prepared in step (iii); (B) preparing a second extract by (p) extracting pulverized seeds of Vitis vinifera with water, and the filtering the resultant; (q) extracting the filtrate prepared in step (p) with ethanol, and then filtering the resultant; and (r) drying the filtrate prepared in step (q); and (C) mixing the first extract and the second extract.
- step (i) is conducted by extracting pulverized seeds of Vitis vinifera with a mixed solvent of acetone and water in a volume ratio of 3-5 : 1 , more preferably 4 : 1 , and then filtering the resultant.
- the extraction may be conducted once or repeated several times, preferably 2 to 3 times.
- the filtration of step (i) may be conducted using a conventional method, and the filtrate is collected for the next step.
- test solution 50 mg of each test samples are dissolved in a mixture of acetonitrile and diluted phosphoric acid (5:95) to prepare a test solution having a volume of 10 ml.
- Reference solutions 1 , 2, and 3, and test solutions 1 and 2 are analyzed twice using liquid chromatography described below.
- Calibration curve of the reference solution are set using the concentration of the reference solutions and a ratio of main peak and IS peak (A proa nthocyan ⁇ d ⁇ n/ABH ⁇ ), and calculated as follows.
- Example 1 Serum of each of the test groups was diluted in a ratio 1 :8000, and subtype of Total IgG antibody was measured. Th2 type IgGI was not changed (FIG. 12), but Th1 type Cll-specific lgG2a was decreased in the animals into which the Vitis vinifera pip extract was injected compared with the animals into which saline was injected (FIG. 13).
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention provides an improved process for preparing a Vitis vinifera pip extract. And also, the present invention provides a pharmaceutical composition for preventing or treating rheumatoid arthritis including the Vitis vinifera pip extract as an active ingredient.
Description
PROCESS FOR PREPARING VITIS VINIFERA PIP EXTRACT AND
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING
RHEUMATOID ARTHRITIS COMPRISING THE SAME
TECHNICAL FIELD
The present invention relates to a process for preparing a Vitis vinifera pip extract and a pharmaceutical composition for preventing or treating rheumatoid arthritis including the Vitis vinifera pip extract as an active ingredient.
BACKGROUND ART
Genus Vitis is a climbing plant belonging to order Rhamnales and family Vitaceae and naturally grows or is cultivated all over the earth except for equator areas and areas with latitude of 50° or higher. 11 genera and 700 species belong to the family Vitaceae. Vitis vinifera, Vitis labrusca, Vitis riparia, Vitis rupestris, Vitis berladieri, Vitis coignetiae, Vitis amurensis, and the like are cultivated for fruits.
An extract, which is obtained from the seeds of Vitis vinifera, includes (-)epicatechin, proanthocyanidins B1 and B2, (+)catechin, and a mixture of their polymerization derivatives, which are known as procyanidol or flavanol oligomer (GB-A-1541469 and FR-A-2092743). It is known that the extract is useful for the treatment of circulatory diseases.
U.S. Patent Publication No. 2003/0165589 discloses that Vitis vinifera, preferably an extract obtained from leaves of Vitis vinifera, inhibits Nitric Oxide-synthase (NO-synthase), and thus can be used to inhibit a variety of diseases related to NO-synthase, such as cellular differentiation and/or proliferation, growth of epidermis and/or hyperproliferative disorders, degradation and destruction of cells, and immunological and/or inflammatory processes. Meanwhile, U.S. Patent Publication No. 2006/0280811 discloses formulations for the treatment of arthritis including saligenin or Salix rubra extract; boswellic acid or
Boswellia serrata extract; procyanidins from Vitis vinifera or from Camellia sinensis, preferably complexed with phospholipids, rhein, or lipophilic derivatives thereof; N-acetyl-glucosamine; and glucronic acid or glucuronolactone. According to U.S. Patent Publication No. 2006/0280811 , the procyanidins synergistically interact with cyclooxygenanse-2 (COX-2) inhibiting components present in the Salix and Boswellia extract. However, it is not disclosed what component specifically acts as active ingredients for the treatment of arthritis. The procyanidins can be obtained using an extracting method disclosed in GB-A-1541469 (and FR-A-2092743) or U.S. Patent No. 5,484,594 (EP 348,781). U.S. Patent No. 4,963,527 discloses cosmetic compositions containing phospholipid complexes of Vitis vinifera extract, which can be also obtained as described in FR-A-2092743 (i.e., GB-A-1541469).
According to GB-A-1541469 (and FR-A-2092743), an acetone-water mixture containing 3 to 4 volumes of acetone to one volume of water is used as a first extraction solvent in order to extract oligomers and remove impurities by precipitation (i.e., partial precipitation). That is, Vitis vinifera (e.g., seed) is treated with the acetone-water mixture containing 3 to 4 volumes of acetone to one volume of water, and acetone is removed by distillation. Then, precipitated impurities are filtered, and the aqueous filtrate is treated with a water-immiscible organic solvent such as ethyl acetate. Then, the organic solvent is removed, and the residue is removed. The remaining impurities are removed by precipitation by adding sodium chloride, and the aqueous filtrate is treated with ethyl acetate and chloroform. According to GB-A-1541469, since partial precipitation does not occur when excessive amount of water is used, the use of excessive amount of water cannot be effectively applied to mass production. Extraction disclosed in GB-A-1541469 should be conducted using a mixture including excessive amount of acetone as a first extraction solvent at the boiling temperature of acetone (at about 57 "C) and the excessive amount of acetone should be removed by distillation. Therefore, costs for the extraction may be increased due to heating conditions and long evaporation time, and environmental contamination may be also caused due to the use of excessive amount of acetone. In addition, acetone may remain in the finally obtained extract. Furthermore, the extraction process may be
prolonged since treatment using a water-immiscible organic solvent such as ethyl acetate and removal of the ethyl acetate are necessary before adding sodium chloride.
U.S. Patent No. 5,484,594 (European Patent No. 348,781) discloses a selective extraction method using ultrafiltration on membranes of cut-off from 3000 to 600; and using ethers, or esters or mixtures of ethyl acetate and aromatic hydrocarbons. However, costs for extraction is high since more extraction processes are necessary compared with the method disclosed in GB-A-1541469, and additional equipments, such as equipment for ultrafiltration, needs to be used.
Meanwhile, Korean Patent No. 10-0509119 discloses that a procyanidin oligomer (catechin^-phloroglucinol), obtained from Ulmi cortex using a mult-step extraction process including column chromatography, inhibits activity of matrix metalloproteinase (MMP), and thus can be efficiently used to prevent and treat diseases such as cancer migration, periodontal diseases, rheumatoid arthritis, inflammation, hyperparathyroidism, diabetes, corneal ulcer, osteoporosis, stomach ulcer, trauma, wrinkles, acne, AIDS, burn, arteriosclerosis, bone fracture. However, it does not disclose the method of obtaining Vitis vinifera extract. Korean Patent No. 10-0509119 discloses only that procyanidin oligomers are abundant in Ulmi cortex, grape seeds, rhubarb, Pleuropterus multiflorus, camphor trees, cinnamon, Thuja orientalis, camellia, millet, buckwheet, oak, and the like, but it is not disclosed that extract of graph seeds, particularly, Vitis vinifera extract could be related to rheumatoid arthritis.
DETAILED DESCRIPTION OF THE INVENTION
TECHNICAL PROBLEM
The present inventors conducted research in order to develop an improved process for preparing a Vitis vinifera extract through a simple process. As a result, the present inventors have found that, by extracting Vitis vinifera seeds using a water-acetone mixture containing a relatively small amount of acetone as a first extraction solvent, removing acetone by distillation, and then directly treating the resultant aqueous layer with sodium chloride, the extraction can be performed at room
temperature (at about 25 "C) and also distillation can be simplified. In addition, it has been also found that the extraction process can be simplified since it is not necessary to perform extraction step using a water-immiscible organic solvent.
The present inventors have also found an improved process for preparing the extract, the process including separately preparing a first extract and a second extract, and mixing them. That is, the extract can be prepared by preparing a first extract obtained by conducting extraction using an acetone-water mixture and then conducting extraction using ethyl acetate; preparing a second extract obtained by conducting extraction using only water as an extraction solvent and conducting extraction using ethanol; and mixing the first extract and the second extract. According to the process, the amount of acetone used can be decreased, extraction process can be simplified since sodium chloride saturation and chloroform extraction are not necessary, and environmental contamination caused by using organic solvents can be minimized. In particular, the yield of the extract can be increased by about 10 times. The present inventors conducted research on various pharmacological effects of a Vitis vinifera pip extract and discovered that the Vitis vinifera pip extract has excellent effects on preventing and treating rheumatoid arthritis. It is very surprising since it has not been reported that the Vitis vinifera extract could be related to rheumatoid arthritis.
Thus, the present invention provides improved processes for preparing a Vitis vinifera pip extract.
The present invention also provides a pharmaceutical composition for preventing or treating rheumatoid arthritis comprising a Vitis vinifera pip extract as an active ingredient.
TECHNICAL SOLUTION
According to an aspect of the present invention, there is provided a process for preparing a Vitis vinifera pip extract, the process comprising: (a) extracting pulverized seeds of Vitis vinifera at room temperature with a mixed solvent of acetone and water in a volume ratio of 1 : 1-2, and then filtering the resultant; (b) distilling the filtrate prepared in step (a) to remove acetone, saturating with sodium chloride, and then filtering the
resultant; (c) extracting the filtrate prepared in step (b) with ethyl acetate, and then concentrating the resultant; and (d) adding chloroform to the concentrate prepared in step (c), and then precipitating the resultant by filtration.
The volume ratio of acetone and water in the mixed solvent of step (a) may be 1 : 1.5. The extraction of steps (a) and (c) may be repeated 2 to 3 times. The distillation of step (b) may be conducted at 500C or less under a reduced pressure and the filtering of step (b) may be conducted after standing for 2 to 3 hours from the saturation with sodium chloride. The concentrating in step (c) may be conducted to a volume of 0.4 to 0.7 times of the total volume of the extract. According to another aspect of the present invention, there is provided a process for preparing a Vitis vinifera pip extract, the process comprising: (A) preparing a first extract by (i) extracting pulverized seeds of Vitis vinifera with a mixed solvent of acetone and water in a volume ratio of 3-5 : 1 , and then filtering the resultant; (ii) concentrating the filtrate prepared in step (i) to remove acetone, and then filtering the resultant; (iii) extracting the filtrate prepared in step (ii) with ethyl acetate; and (iv) drying the extract prepared in step (iii); (B) preparing a second extract by (p) extracting pulverized seeds of Vitis vinifera with water, and the filtering the resultant; (q) extracting the filtrate prepared in step (p) with ethanol, and then filtering the resultant; and (r) drying the filtrate prepared in step (q); and (C) mixing the first extract and the second extract. The volume ratio of acetone and water in the mixed solution of step (i) may be 4 :
1. The extraction of step (iii) or (q) may be repeated 2 to 3 times. Step (iii) may further comprise dehydrating the resulting extract. The drying of step (iv) may be conducted by concentrating the extract prepared in step (iii) to remove ethyl acetate, dissolving the concentrate in water, and then spray-drying the resultant. The drying of step (r) may be conducted by spray-drying the filtrate prepared in step (q) or by concentrating the filtrate prepared in step (q), and then spray-drying the concentrate.
The mixing ratio of the first extract and the second extract may be 1 : 0.5-1.5 by weight.
It is preferable that the obtained Vitis vinifera pip extract in the above processes have 80-130% of Procyanidolic value (PCV); 30% or less of (+)catechin and (-)epicatechin; and 95-105% of proanthocyanidin.
According to still another aspect of the present invention, there is provided a pharmaceutical composition for preventing or treating rheumatoid arthritis comprising a Vitis vinifera pip extract as an active ingredient and a pharmaceutically acceptable carrier. Preferably, the Vitis vinifera pip extract is prepared in accordance with the above processes. More preferably, the Vitis vinifera pip extract has 80-130% of Procyanidolic value (PCV); 30% or less of (+)catechin and (-)epicatechin; and 95-105% of proanthocyanidin.
ADVANTAGEOUS EFFECTS
According to the present invention, extraction is conducted using a water-acetone mixture having relatively small amount of acetone as a first extraction solvent. Therefore, acetone can be simply distilled and residual solvent can be minimized. Furthermore, a heating process is not necessary since the extraction can be performed at room temperature (at about 250C), and extraction using a water-immiscible organic solvent is not necessary before adding sodium chloride. Thus, the process for preparing a Vitis vinifera pip extract according to the present invention can be conducted simply and cost-effectively, and thus can be suitably applied to industrial mass production. In addition, according to a process for preparing a Vitis vinifera pip extract by separately preparing a first extract and a second extract and mixing them, the amount of acetone can be decreased, extraction process can be simplified since sodium chloride saturation and chloroform extraction are not necessary, and environmental contamination caused by using organic solvents can be minimized. In particular, the yield of the extract can be increased by about 10 times.
Furthermore, the Vitis vinifera pip extract prepared according to the process, as a natural extract, has excellent safety and shows excellent preventing and treating effects of rheumatoid arthritis, e.g., in a collagen induced arthritis (CIA) animal model.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a graph illustrating arthritis scores of collagen induced arthritis (CIA) animals, CIA animals into which 100 mg/kg of Vitis vinifera pip extract (GSPE) is injected in 5 consecutive intraperitoneal injection, and CIA animals into which saline is injected 5 consecutive intraperitoneal injection, observed for 10 weeks. FIG. 2 illustrates photographs of joint regions of CIA animals, CIA animals into which the Vitis vinifera pip extract is injected, and normal animals before sacrificing them.
FIG. 3 illustrates the degree of destruction of joints and cartilaginous tissues of CIA animals, CIA animals into which each of 50 mg/kg and 10 mg/kg of the Vitis vinifera pip extract is injected, and normal animals after sacrificing them, through tissue staining.
FIG. 4 illustrates the amount of Type Il collagen-specific antibodies (anti-CII
IgGI and anti-CII lgG2a) in serums of CIA animals into which 100 mg/kg of the Vitis vinifera pip extract is injected, CIA animals into which saline is injected, and normal animals. FIG. 5 illustrates the amount of IL-17 and TNF-α measured by enzyme-linked immunosorbent assay (ELISA), in a culture supernatant prepared by co-culturing thymus CD4+ T cells and spleen CD11c+ dendritic cells in a ratio of 10:1 for 3 days, which are obtained from CIA animals into which 100 mg/kg of the Vitis vinifera pip extract is injected or CIA animals into which saline is injected. FIG. 6 illustrates the amount of IL-17 and IL-4 in a culture supernatant prepared by co-culturing the cells obtained in the same manner as described in FIG. 5 for 3 days in culture media unsupplemented or supplemented with 10 μg/ml and 20 μg/ml of the Vitis vinifera pip extract with stimulation of anti-CD3 using ELISA.
FIG. 7 illustrates the degree of expression of IL-17 mRNA, using a real-time transcriptase-polymerase chain reaction (PCR), from draining lymph nodes (dLN) which are obtained from CIA animals into which 50 mg/kg and 10 mg/kg of Vitis vinifera pip extract or saline are respectively injected, and cultured in culture media unsupplemented or supplemented with 10 μg/ml of the Vitis vinifera pip extract with stimulation of anti-CD3, CII, and lipopolysaccharide (LPS) for 3 days. FIGS. 8 and 9 illustrate the results of co-culturing thymus CD4+ T cells and spleen CD11c+ dendritic cells obtained from a CIA animal model and an autoimmune
arthritis animal model IL-I Ra-/- in a ratio of 10:1 in culture media unsupplemented or supplemented with 10 μg/ml of the Vitis vinifera pip extract with stimulation of anti-CD3, CPG or CII, for 6 days, using a fluorescence activated cell sorter (FACS).
FIG. 10 is a graph illustrating arthritis score of CIA animals into which saline, celecoxib, or 10% DMSO are injected via intraperitoneal injection, or the Vitis vinifera pip extract is orally administered.
FIG. 11 illustrates a joint piece of CIA animals, dyed with hematoxylin and eosin, into which saline, celecoxib, or 10% DMSO are injected via intraperitoneal injection, or the Vitis vinifera pip extract is orally administered. FIGS. 12 and 13 illustrate subtypes of Total IgG antibody of CIA animals into which saline is injected via intraperitoneal injection or the Vitis vinifera pip extract is orally administered.
FIGS. 14 to 16 illustrate the amount of IL-17, TNF alpha, and IL-1β in CIA animals into which saline, celecoxib, or 10% DMSO are injected via intraperitoneal injection or the Vitis vinifera pip extract is orally administered.
BEST MODE FOR CARRYING OUT THE INVENTION
The present invention includes a process for preparing a Vitis vinifera pip extract, the process comprising: (a) extracting pulverized seeds of Vitis vinifera at room temperature with a mixed solvent of acetone and water in a volume ratio of 1 : 1-2, and then filtering the resultant; (b) distilling the filtrate prepared in step (a) to remove acetone, saturating with sodium chloride, and then filtering the resultant; (c) extracting the filtrate prepared in step (b) with ethyl acetate, and then concentrating the resultant; and (d) adding chloroform to the concentrate prepared in step (c), and then precipitating the resultant by filtration.
Pulverized seeds of Vitis vinifera may be prepared by compressing WWs vinifera to obtain bark, seed, and branch, washing the resultants with water, drying the same using an oven, isolating the seeds, and then pulverizing the seeds using a conventional method.
In the process of the present invention, a mixed solvent of acetone and water having a lower amount of acetone compared with that used in a conventional extraction (e.g., disclosed in GB-A-1541469) is used as a first extraction solvent and the first extraction process is conducted at room temperature (at about 250C) without heating. In the mixed solvent of acetone and water used herein, the volume ratio of acetone to water may be in the range of 1 : 1-2, and preferably about 1 : 1.5. The first extraction may be conducted once or repeated several times, preferably 2 to 3 times. The filtration of step (a) may be conducted using a conventional method, and the filtrate is collected for the next step. The process of the present invention includes distilling the filtrate prepared in step (a) to remove acetone, saturating with sodium chloride, and then filtering the resultant [step (b)]. During the distillation, acetone having a relatively low boiling point is removed, and thus impurities dissolved in acetone are precipitated. The distillation may be performed using a conventional method, for example, under a reduced pressure. The distillation may be performed at about 500C or less under a reduced pressure. The extract obtained using the distillation is not subjected to extraction using an organic solvent, but saturated with sodium chloride and then filtered. If the extract (i.e., extract in which acetone is evaporated) is saturated with sodium chloride, impurities such as tannin are precipitated and removed during the filtration. In the precipitation of impurities through the saturation with sodium chloride and filtration, the filtration may be conducted after standing for 2 to 3 hours from the saturation with sodium chloride. The filtration may be conducted using a conventional method, and the filtrate is collected for the next step.
The process of the present invention includes extracting the filtrate prepared in step (b) with ethyl acetate, and then concentrating the resultant [step (c)]. The extraction using ethyl acetate (second extraction) may be conducted once or repeated several times, preferably 2 to 3 times. The concentrating may be conducted to a volume of 0.4 to 0.7 times of the total volume of the obtained extract.
The process of the present invention includes adding chloroform to the concentrate prepared in step (c), and then precipitating the resultant by filtration [step (d)]. When chloroform is added to the concentrate, active ingredients including
oligomers which are not dissolved in chloroform are precipitated. The Vitis vinifera pip extract may be simply isolated by filtering the precipitate. The precipitate prepared by the filtration may be dried using a conventional method to obtain dried powder. The drying may be conducted under a reduced pressure, for example, at 50 °C or less under a reduced pressure.
The present invention also includes a process for preparing a Vitis vinifera pip extract, the process comprising: (A) preparing a first extract by (i) extracting pulverized seeds of Vitis vinifera with a mixed solvent of acetone and water in a volume ratio of 3-5 : 1 , and then filtering the resultant; (ii) concentrating the filtrate prepared in step (i) to remove acetone, and then filtering the resultant; (iii) extracting the filtrate prepared in step (ii) with ethyl acetate; and (iv) drying the extract prepared in step (iii); (B) preparing a second extract by (p) extracting pulverized seeds of Vitis vinifera with water, and the filtering the resultant; (q) extracting the filtrate prepared in step (p) with ethanol, and then filtering the resultant; and (r) drying the filtrate prepared in step (q); and (C) mixing the first extract and the second extract.
Pulverized Vitis vinifera seeds may be prepared as described above. The extract may be prepared by separately preparing a first extract and a second extract and mixing them. Thus, according to the process of the present invention, the amount of acetone may be decreased. And also, since sodium chloride saturation and chloroform extraction are not necessary, the process may be simplified and environmental contamination that may be caused by organic solvents may be minimized. In addition, the yield of the extract may be increased by about 10 times.
In the preparation of the first extract, step (i) is conducted by extracting pulverized seeds of Vitis vinifera with a mixed solvent of acetone and water in a volume ratio of 3-5 : 1 , more preferably 4 : 1 , and then filtering the resultant. The extraction may be conducted once or repeated several times, preferably 2 to 3 times. The filtration of step (i) may be conducted using a conventional method, and the filtrate is collected for the next step.
In the preparation of the first extract, step (ii) is conducted by concentrating the filtrate prepared in step (i) to remove acetone, and then filtering the resultant. During the concentration, acetone having a relatively low boiling point is removed, and thus
impurities dissolved in acetone are precipitated. The concentration may be conducted using a conventional concentration under a reduced pressure (or distillation under a reduced pressure), for example, using distillation under the condition of a reduced pressure. The precipitate is removed by filtration, and the filtrate is collected. In the preparation of the first extract, step (iii) is conducted by extracting the filtrate prepared in step (ii) with ethyl acetate. The extraction using ethyl acetate (second extraction) may be conducted once or repeated several times, preferably 2 to 3 times. In addition, step (iii) may further include a dehydration process, e.g., using anhydrous sodium sulfate, after the extraction using ethyl acetate. In the preparation of the first extract, step (iv) is conducted by drying the extract prepared in step (iii). The drying may be conducted using a conventional method, for example, at 50 °C or less under a reduced pressure. More preferably, the drying may be conducted by concentrating the extract prepared in step (iii) to remove ethyl acetate, dissolving the concentrate in water, and then spray-drying the resultant. In the preparation of the second extract, step (p) is conducted by extracting pulverized seeds of Vitis vinifera with water, and the filtering the resultant; and step (q) is conducted by extracting the filtrate prepared in step (p) with ethanol, and then filtering the resultant. The extraction of step (q) may be conduced once or repeated several times, preferably 2 to 3 times. In the preparation of the second extract, step (r) is conducted by drying the filtrate prepared in step (q). The drying of step (r) may be conducted by spray-drying the filtrate prepared in step (q); or concentrating the filtrate of step (q) and then spray-drying the concentrate. The concentration may be conducted into a volume of 0.4 to 0.7 times of the total volume of the filtrate prepared in step (q), but is not limited thereto.
The mixing the first extract and the second extract may be conducted by simply mixing the extracts. The mixing ratio of the first extract and the second extract may be 1 : 0.5-1.5 by weight.
The Vitis vinifera pip extract prepared according to the process of the present invention has 80-130% of Procyanidolic value (PCV); 30% or less of (+)catechin and (-)epicatechin; and 95-105% of proanthocyanidin.
The "procyanidolic value (PCV)" used herein is calculated as follows. © Preparation of reference solution
100 mg of Vitis vinifera pip extract standard is precisely measured and mixed with isopropanol to form a solution having a volume of 50 ml. 10 ml of the solution is mixed with 10 ml of 3M hydrochloric acid, and then the obtained solution is mixed with isopropanol to prepare a reference solution having a volume of 50 ml. © Preparation of test solutions
100 mg of each test samples are processed in the same manner of preparation of the standard solution to prepare test solutions. © Measurement
10 ml of each of the test solutions and the reference solutions are respectively added to 5 test tubes and the test tubes are capped. Then, the test tubes are heated in a water bath at 100 0C for 45 minutes. After heating, the test tubes are cooled in cold water, and 2 ml of the solution obtained from each of the test tubes is mixed with 20 ml of isopropanol. Absorbance is measured at 550 nm for the test solution and the reference solution, using isopropanol as a control solution, and 5 average absorbance values were calculated. ® Calculation
PCV = 105 X [A(t) X Mt X (100-Et)] / [A(s) X M X (100-E)] A(t): mean absorbance of the test solutions
A(s): mean absorbance of the reference solutions Mt: mass in mg of the standard M: mass in mg of the test sample Et: water content of the standard (%) E: water content of the test sample (%)
The (+)catechin and (-)epicatechin are quantified as follows. © Preparation of reference solution
50 mg of each of (+)catechin standard and (-)epicatechin standard are dissolved in a mixture of acetonitrile and diluted phosphoric acid (5:95) to prepare a reference solution having a volume of 100 ml.
® Preparation of test solutions
50 mg of each test samples are dissolved in a mixture of acetonitrile and diluted phosphoric acid (5:95) to prepare a test solution having a volume of 10 ml. (D Assay condition - Column: a column packed with octadecylsilylated silica gel (0.46 X 25 cm, 5 urn)
- Mobile phase Table 1
Mobile phase A: diluted phosphoric acid solution (0.3%, v/v) Mobile phase B: acetonitrile
- Flow rate: 0.7 ml/min
- Detector: UV detector (wavelength: 278 nm)
- Injection volume: 10 ul © Calculation
Content of catechine, expressed as epicatechine (%)
= [A1 X Me X 100 X 100] / [Ae X M1 X (100-E) X 10]
Content of epicatechine (%)
= [A2 X Me X 100 X 100] / [Ae X M1 X (100-E) X 10]
A1 : peak area of catechine in the test solution
A2: peak area of epicatechine in the test solution
Ae: peak area of epicatechine in the reference solution
Me: mass in mg of epicatechine in the reference solution
M1 : mass in mg of the extract in the test solution
E: water content in the extract (%)
In addition, the "amount of proanthocyanidin" is calculated using the method described below.
CD Preparation of internal standard solution
30.0 mg of 2,6-di-tert-butyl-4-methylphenol (BHT) is added to a 100 ml flask and mobile phase is added thereto up to the marked line to prepare an internal standard solution.
(D Preparation of test solution 1
10 mg of a sample is added to a 10 ml flask and the then dissolved in 5 ml of the internal standard solution, and the internal standard solution is added thereto up to the marked line to prepare a detection solution 1.
® Preparation of test solution 2
10 mg of a sample is added to a 10 ml flask and the then dissolved in 5 ml of the internal standard solution, and the internal standard solution is added thereto up to the marked line to prepare a detection solution 2. (4) Preparation of calibration curve of reference solution
- Reference solution 1: 8 mg of proanthocyanidin standard is added to a 10 ml flask and dissolved in 5 ml of the internal standard solution, and the internal standard solution is added thereto up to the marked line to prepare reference solution 1.
- Reference solution 2: 10 mg of proanthocyanidin standard is added to a 10 ml flask and dissolved in 5 ml of the internal standard solution, and the internal standard solution is added thereto up to the marked line to prepare reference solution 2.
- Reference solution 3: 12 mg of proanthocyanidin standard is added to a 10 ml flask and dissolved in 5 ml of the internal standard solution, and the internal standard solution is added thereto up to the marked line to prepare reference solution 3. © Assay condition
- Column: PL Gel Column (7.6 X 300 mm, 5 um) or similar column
- Detector: UV detector (wavelength: 280 nm)
- Mobile phase: mixture of tetrahydrofuran and lithium bromide solution (95:5)
* lithium bromide solution: 1.04 g of lithium bromide is added to a 1000 ml flask and water is added thereto up to the marked line.
- Flow rate: 1.0 ml/min
- Injection volume: 10 uL
- Run time: 15 minutes © Method
Reference solutions 1 , 2, and 3, and test solutions 1 and 2 are analyzed twice using liquid chromatography described below. Calibration curve of the reference solution are set using the concentration of the reference solutions and a ratio of main peak and IS peak (Aproanthocyanιdιn/ABHτ), and calculated as follows.
© Calculation
- Tϊ% = {[(Aproaπthocyamdιn/ABHτ)test " a] / b} X (1 / C test) X 100 Aproanthocyanidin = peak area of proanthocyanidins in the test solution
ABHT = peak area of BHT in the test solution a = intercept of the Calibration Curve of reference solution b = slope of the Calibration Curve of reference solution C test = concentration of the test solution (mg/ml) - Content of proanthocyanidins (%) = Tϊ% x [(100-KFstd)/(100-KFtest)]
KFstd = water content in the reference substance (%) KFtest = water content in the test sample (%)
The present invention includes a pharmaceutical composition for preventing or treating rheumatoid arthritis comprising a Vitis vinifera pip extract as an active ingredient and a pharmaceutically acceptable carrier.
The Vitis vinifera pip extract may be prepared in accordance with the above processes. More preferably, the Vitis vinifera pip extract has 80-130% of Procyanidolic value (PCV); 30% or less of (+)catechin and (-)epicatechin; and 95-105% of proanthocyanidin.
As described in Experimental Examples below, the Vitis vinifera pip extract prepared according to the present invention shows excellent preventing and treating effects of rheumatoid arthritis, e.g., in a collagen induced arthritis (CIA) animal model.
That is, when 100 mg/kg of the Vitis vinifera pip extract was injected into a CIA animal via intraperitoneal injection, arthritis score was significantly decreased (FIGS. 1 and 2). Furthermore, the relief of arthritis was observed in a rheumatoid arthritis
animal model (IL-Ra-/-) having chronic inflammatory arthritis. As a result of histological assay, when 100 mg/kg of the Vitis vinifera pip extract was injected, the degree of joint destruction of the animal was similar to that of a normal mouse, and destruction of cartilage was improved (FIG. 3). In addition, as a result of serologic tests, when 100mg/kg of the Vitis vinifera pip extract was injected, the level of Th2 type anti-CII IgGI was not changed, but the production of Cll-specific Th1 type lgG2a is decreased (FIG. 4). It can be seen that rheumatoid arthritis can be efficiently treated' by administering the Vitis vinifera pip extract since the production of Cll-specific TM type lgG2a is decreased. In addition, the amount of IL-17 and TNF alpha, known as inflammatory cytokines of rheumatoid arthritis, was significantly decreased when the Vitis vinifera pip extract was injected (FIG. 5), and an inflammatory cytokine IL-17 showed reverse relationship with anti-inflammatory cytokine IL-4 when Vitis vinifera pip extract was treated in vitro (FIG. 6). The profile of IL-17 at transcription level was also observed in the same pattern. When stimulating with CII or LPS and then treating with Vitis vinifera pip extract in vitro, the expression level of mRNA of IL-17 increased by CII or LPS was decreased (FIG. 7).
Since rheumatoid arthritis is related to excessive activity of immune cells (particularly, chronic inflammatory T cells), the regulation of CD4 T cells may be a target for the treatment. When CIA animals and IL-I Ra-/- animals were treated with a Vitis vinifera pip extract, induction of Foxp3+ regulatory CD4 T cells was increased. When CD4 T cell in CIA animals were treated with CII and Vitis vinifera pip extract, induction of Foxp3+ regulatory CD4 T cells were increased compared with the group treated only with CII (FIGS. 8 and 9). We expect that proliferation of chronic inflammatory T cells may be efficiently inhibited through generation of Cll-specific regulatory CD4 T cells by the Vitis vinifera pip extract.
Thus, it can be seen that a Vitis vinifera pip extract has excellent preventing and treating rheumatoid arthritis by inhibiting generation of inflammatory cytokines and inducing anti-inflammatory cytokines and regulatory T cells. The pharmaceutical composition of the present invention includes a pharmaceutically acceptable carrier, and can be formulated according to conventional
methods into oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, or aerosols; external dosage forms; susppository; or sterile injection solution. Preferably, the pharmaceutical composition of the present invention may be formulated into a tablet form. The pharmaceutically acceptable carrier can be lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, or mineral oil. The pharmaceutical composition may further include a dilluent or an excipient, such as filler, expander, binder, humectant, disintegrant, or surfactant. A solid oral formulation can be a tablet, a pill, a powder, a granule, or a capsule. Such solid formulations may include at least one excipient selected from, for example, starch, calcium carbonate, sucrose, lactose, and gelatin. In addition, such solid formulations may further include a lubricant, such as magnesium stearate or talc. A liquid oral formulation can be a suspension, a solution, an emulsion, or syrup. In addition, the liquid oral formulation may include a dilluent, such as water, liquid paraffine; humectant; sweetening agent; odorant; or preservative. A parenteral formulation can be a sterile aqueous solution, a non-aqueous solution, a suspension, an emulsion, a lyophilized formulation, or a suppository. Non-aqueous solvents or suspending agents can be propylene glycol, polyethylene glycol, natural oil, such as olive oil, or injectable esters, such as ethylolate. Vehicles for suppository can be witepsol, macrogol, Tween 61, cacao butter, Laurin, or glycerogelatine.
In the pharmaceutical composition according to the present invention, a dose of the extract of the Vitis vinifera pip extract may vary depending on patient's state or body weight, seriousness of disease, dosage forms, administration routes, and the period of administration, and can be appropriately determined by a person having ordinary skill in the art. For example, the Vitis vinifera pip extract can be administered in an amount of 1 to 100 mg/kg, preferably 5 to 50 mg/kg, more preferably 5 to 10 mg/kg, per day. The administration can be completed once or through several times per day. The pharmaceutical composition of the present invention can be also administered in combination with other therapeutic agent(s) for rheumatoid arthritis. When
administered as a combination, the therapeutic agent(s) can be administered sequentially or at the same time. When administered as a combination, each dose may be determined to minimum amounts showing maximum therapeutic effect, and can be appropriately determined by a person having ordinary skill in the art. The pharmaceutical composition of the present invention can be administered to mammals, such as rats, mouse, livestock, or human beings, through various routs, e.g., orally, rectally, intravenously, intramuscularly, subcutaneously, preferably orally.
Hereinafter, the present invention will be described more specifically by the following working examples. However, the following working examples are provided only for illustrations and thus the present invention is not limited to or by them.
Example 1 : Preparation of Vitis vinifera pip extract
Bark, seeds, branch of Vitis vinifera prepared by compressing Vitis vinifera were washed with water and dried in a rotating oven, and seeds of Vitis vinifera were isolated. 1 kg of the seeds were pulverized and subjected to extraction at room temperature by adding 500 ml of the mixed solution of purified water (300 ml) and acetone (200 ml). The extraction was repeated three times, and the extracts were gathered and filtered. The filtrate was distilled at 500C or less under a reduced pressure to remove acetone, and the resultant was saturated with sodium chloride. The resultant was placed at room temperature for 3 hours and then filtered. The filtrate was subjected to extraction three times using 250 ml of ethyl acetate, and dehydrated using anhydrous sodium sulfate. The extract was concentrated until the volume of the extract reached about 125 ml. About 600 ml of chloroform was added to the concentrate to form a precipitate, and the resultant was filtered. The precipitate was dried at 500C or less in a vacuum oven to obtain about 3.5 g of brown Vitis vinifera pip extract powder. The obtained extract was hydrolyzed by heating in a diluted acid solution, and PCV was measured by quantifying procyanidolic oligomers. As a result, the PCV was about 105. In addition, when measured as described in the above, the amount of proanthocyanidin was 103%. Thus, the extract includes a large amount of oligomers in which at least two monomers such as (+)catechin and (-)epicatechin were polymerized.
Example 2: Preparation of Vitis vinifera pip extract
Bark, seeds, branch of Vitis vinifera prepared by compressing Vitis vinifera were washed with water and dried in a rotating oven, and seeds of Vitis vinifera were isolated. 1 kg of the seeds of Vitis vinifera was pulverized and subjected to extraction using 500 ml of an acetone water solution (acetone/water = 8/2, v/v). The extraction was repeated three times, and the extract was gathered and then filtered. The filtrate was concentrated under a reduced pressure to remove acetone and then filtered. The filtrate was subjected to extraction three times using 250 ml of ethyl acetate and dehydrated using anhydrous sodium sulfate. The extract was concentrated under a reduced pressure to remove ethyl acetate, the concentrate was dissolved in 500 ml of water, and the solution was spray-dried to obtain about 20 g of extract powder (first extract).
Bark, seeds, branch of Vitis vinifera prepared by compressing Vitis vinifera were washed with water and dried in a rotating oven, and seeds of Vitis vinifera were isolated. 1 kg of the seeds of Vitis vinifera was pulverized and subjected to extraction using 500 ml of purified water. The extraction was repeated three times, and the extract was gathered and then filtered. The filtrate was subjected to extraction three times using 250 ml of ethanol and then filtered. The filtrate was concentrated under a reduced pressure, and the concentrate was spay-dried to obtain about 15 g of extract powder (second extract).
The first extract and the second extract were mixed to obtain about 35 g of Vitis vinifera pip extract. The obtained extract was hydrolyzed by heating in a diluted acid solution, and PCV was measured by quantifying procyanidolic oligomers. As a result, the PCV was about 98. In addition, when measured as described in the above, the amount of proanthocyanidin was 98.5%. Thus, the extract includes a large amount of oligomers in which at least two monomers such as (+)catechin and (-)epicatechin were polymerized.
Experimental Example 1 : Evaluation of therapeutic effect on arthritis when injected via intraperitoneal injection
1. Preparation of animal model and administration of the Vitis vinifera pip extract Collagen induced arthritis (CIA) animal models were prepared and the Vitis vinifera pip extract prepared according to Example 1 was administered as follows. 6-7 week old male DBA-1 mice were used. Type 2 collagen (CII) was dissolved in 0.1 N acetic acid solution to a concentration of 4 mg/ml and dialyzed with a dialysis buffer (5OmM Tris, 0.2N NaCI). The resultant was mixed with the same volume of Complete Freud's adjuvant (CFA, Chondrex) containing M. tuberculosis, and 100 μi (i.e., 100 /^/100 μg) of immunogen was hypodermically injected into the base of tail of the mice (first injection).
After one week from the first injection, 200 μi of each of 100 mg/kg of the Vitis vinifera pip extract (dissolved in saline) and 200 μi of saline as a control group were injected into the mice via intraperitoneal injection. After one week (i.e., after two week from the first injection), the CII was mixed with the same volume of incomplete Freud's adjuvant (IFA, Chondrex), and 100 μi (i.e., 100 μihOO μg) of the mixture was injected into one hind leg (second injection). After the second injection, 100 mg/kg of the Vitis vinifera pip extract and saline as a control group were injected via intraperitoneal injection every three days, four times in total.
5 mice were used for each group, and evaluation was conducted for 10 weeks. When arthritis score is significantly changed, each mouse was sacrificed and the activities of arthritis in blood, cells, and joint tissues were measured and various in vitro experiments were conducted.
2. Evaluation of therapeutic activity of Vitis vinifera pip extract on rheumatoid arthritis in CIA animal
(2-1) Evaluation of average arthritis score by Rosoliniec
Three observers who were not aware of the experiment evaluated seriousness of inflammation in joints three times a week from third week to tenth week since the first injection. The evaluation of arthritis was conducted by obtaining an average score obtained from three legs except for the leg into which CII/CFA was injected at the
second injection and an average score obtained by the three observers, based on standard arthritis score by Rosioniec EF. The severity of arthritis was recorded as the mean arthritic index on a 0 to 4 scale.
The score and standard for evaluating arthritis are as follows: 0: no edema and intumescene
1 : slight edema and rubefaction on feet or ankle joint
2: slight edema and rubefaction from ankle joint to metatarsal
3: medium edema and rubefaction from ankle joint to tarsals
4: edema and rubefaction from ankle to the whole leg Since the highest arthritis score for a single leg is 4, the highest arthritis score of a mouse is 16.
It was observed that the arthritis score was gradually decreased in the animal into which the Vitis vinifera pip extract was injected. On the other hand, normal outbreak of arthritis was observed in the CIA animals and the CIA animals into which saline was injected as a control group. Thus, clinical symptoms of arthritis were different in the group treated with the Vitis vinifera pip extract and the group not treated withi the Vitis vinifera pip extract (FIG. 1).
In order to identify arthritis score, photographs of the test groups were taken. In the same way as shown in the arthritis score of FIG. 1 , swollen joints of the animal into which the Vitis vinifera pip extract was injected were cured to the degree of that of normal mouse (FIG. 2).
(2-2) Histological test
50 mg/kg and 10 mg/kg of the Vitis vinifera pip extract were injected into the CIA animals prepared above in the same manner as described above. The mice were sacrificed after 8 weeks. A hind leg of each mouse was fixed using 10% formalin, decalcified and paraffined. A joint piece (5-7 μm) was dyed with hematoxylin and eosin. In addition, in order to identify the degree of destruction of cartilage, a histological test was conducted by dyeing with toluidine blue and safranin O. As a result of the histological test, a number of immune cells were infiltrated in joints of the CIA animals and the CIA animals into which saline was injected, and
pannus formation, destruction of cartilage, and bone infiltration were observed. On the other hand, the degree of destruction of joint and cartilage in the mice into which the Vitis vinifera pip extract was injected were similar to that of a normal mouse (FIG. 3).
(2-3) Serologic test (Measuring collagen-specific antibody)
In order to detect subtype of Cll-specific IgG antibody using a serologic test, enzyme-linked immunosorbent assay (ELISA) was used. In mice, IgGI among the subtypes of IgG antibody functions as a regulator inhibiting inflammation. On the other hand, lgG2a functions as a factor promoting and mediating inflammatory reactions. It has been reported that when arthritis is induced in DBA-1 mouse, lgG2a, which typically causes Th1 reaction, is specifically increased.
Serum of each of the test groups was diluted in a ratio 1 :8000, and subtype of Cll-specific serum IgG antibody was measured. As a result, Th2 type IgGI was not changed, but Th1 type Cll-specific lgG2a was decreased in the animal into which the Vitis vinifera pip extract was injected compared with the CIA animal (FIG. 4).
3. Evaluation of regulation of cytokine by the Vitis vinifera pip extract
(3-1) Measuring the amount of IL-17 and TNF alpha After the animals of each group were sacrificed, thymus CD4+ T cells and spleen CD11c+ dendritic cells were isolated and co-cultured in a ratio of 10:1 for 3 days, and the amount of Th17 type cytokine IL-17 and Th1 type cytokine TNF alpha were measured in a supernatant using ELISA.
As a result, the two cytokines were significantly decreased in the animals into which the Vitis vinifera pip extract was injected when compared with the CIA animals (FIG. 5).
(3-2) Effect of Vitis vinifera pip extract on generation of IL-17 and IL-4 by TCR stimulation Thymus CD4+ T cells and spleen CD11c+ dendritic cells obtained from the animals of each group were cultured for 3 days in culture media unsupplemented or
supplemented with 10 μg/ml and 20 μg/ml of the Vitis vinifera pip extract with stimulation of anti-CD3, and IL-17 and IL-4 were measured in the supernatant using ELISA.
The production of IL-17, which is increased by TCR stimulation in the CIA animal into which saline was injected, was decreased depending on the concentration of the Vitis vinifera pip extract treated in vitro. The production of the anti-inflammatory cytokine IL-4 was increased depending on the concentration. On the other hand, the production of IL-17 in the animal into which the Vitis vinifera pip extract was injected was decreased greater than that in the CIA animal in vitro, and the production of IL-4 in the animal into which the Vitis vinifera pip extract was injected was increased greater than that in the CIA animal in vitro (FIG. 6).
As a result, in the animal into which the Vitis vinifera pip extract was injected, cells capable of producing anti-inflammatory cytokine IL-4 were dominant, but Th17 cells were decreased in vitro. This indicates that the Vitis vinifera pip extract regulates the amount of production of inflammatory cytokine and anti-inflammatory cytokine to treat arthritis. In addition, IL-4 is a cytokine capable of inducing regulatory T cells. Thus, it can be seen that the Vitis vinifera pip extract may induce regulatory T cells.
4. Induction of regulatory CD4 T cells and inhibition of Th17 cells by Vitis vinifera pip extract
In order to prove therapeutic mechanism of the Vitis vinifera pip extract for rheumatoid arthritis, immune systems that are induced or inhibited by the Vitis vinifera pip extract were examined.
(4-1) Change of mRNA expression of IL-17 by Vitis vinifera pip extract
50 mg/kg and 10 mg/kg of the Vitis vinifera pip extract, and saline were respectively injected into CIA animals, and they were sacrificed. Draining lymph nodes
(dLN) obtained therefrom were cultured in culture media unsupplemented or supplemented with 10 μg/ml of the Vitis vinifera pip extract with stimulation of anti-CD3,
CII or LPS (lipopolysaccharide) for 3 days. Then, the degree of expression of mRNA of IL-17 was measured using real-time transcriptase-polymerase chain reaction (PCR).
The profile of IL-17 at transcription level was also observed in the same pattern as shown in FIG. 6. When the animal was stimulated with CII or LPS and treated with the Vitis vinifera pip extract in vitro, mRNA of IL-17, which was increased by CII or LPS, was decreased (FIG. 7).
(4-2) Induction of regulatory CD4 T cells by Vitis vinifera pip extract
Thymus CD4+ T cells and spleen CD11c+ dendritic cells obtained from a CIA animals and IL-IRa-/- animals which are another rheumatoid arthritis animal were co-cultured in a ratio of 10:1 in culture media unsupplemented or supplemented with 10 μg/ml of the Vitis vinifera pip extract with stimulation of anti-CD3, CPG or CII for 6 days. Then, the degree of induction of cells expressing Foxp3 was measured using fluorescence activated cell sorter (FACS). The induction of regulatory T cells was more increased by treating the CIA animals with CII and the Vitis vinifera pip extract compared with treating the CIA animals only with the Vitis vinifera pip extract. In addition, in the IL-I Ra-/- animal, when stimulated with the Vitis vinifera pip extract in vitro, induction of Foxp3+ regulatory CD4 T cells was identified (FIGS. 8 and 9). As a result, when treated with CII and the Vitis vinifera pip extract, Cll-specific regulatory cells were produced by increasing induction of CD4 T cells when compared with treating only with CII. Thus, excessive proliferation of chronic inflammatory T cells related to rheumatoid arthritis can be inhibited, and the inflammatory cytokine and anti-inflammatory cytokine are balanced so that the progress of rheumatoid arthritis can be inhibited and rheumatoid arthritis can be cured.
Experimental Example 2. Evaluation of therapeutic effect of oral administration on arthritis
1. Preparation of animal model and administration of Vitis vinifera pip extract
Collagen induced arthritis (CIA) animal models were prepared and the Vitis vinifera pip extract prepared according to Example 2 was administered as follows.
6-7 week old male DBA-1 mice were used. Type 2 collagen (CII) was dissolved in 0.1 N acetic acid solution to a concentration of 4 mg/ml and dialyzed with a dialysis buffer (5OmM Tris, 0.2N NaCI). The resultant was mixed with the same volume of Complete Freud's adjuvant (CFA, Chondrex) containing M. tuberculosis, and 100 μi (i.e., 100 μi/y\Q0 μg) of immunogen was hypodermically injected into the base of tail of a mouse (first injection).
After one week from the first injection, 300 mg/kg of the Vitis vinifera pip extract (dissolved in saline) was orally administered to the mice. Separately, 200 μi of saline,
3 mg/kg of celecoxib (dissolved in 10% DMSO), and 10% DMSO were injected into the mice via intraperitoneal injection. After one week from the oral administration and injection (i.e., after two week from the first injection), the CII was mixed with the same volume of incomplete Freud's adjuvant (IFA, Chondrex), and 100 μi (i.e., 100 μiήOO μg) of the mixture was injected into one hind leg (second injection). After the second injection, 300 mg/kg of the Vitis vinifera pip extract, saline, 3 mg/kg of celecoxib, and
10% DMSO were injected via intraperitoneal injection every three days, four times in total.
5 mice were used for each group, and evaluation was conducted for 8 weeks. When arthritis score is significantly changed, each mouse was sacrificed and the activities of arthritis in blood, cells, and joint tissues were measured and various in vitro experiments were conducted.
2. Evaluation of therapeutic activity of Vitis vinifera pip extract on rheumatoid arthritis in CIA animal
Average arthritis score was measured in the same manner as in (2-1) of
Experimental Example 1 , and the results are shown in FIG. 10. It was observed that the arthritis score of the animal into which the Vitis vinifera pip extract and celecoxib were administered was decreased. On the other hand, normal outbreak of arthritis was observed in the animal into which saline and 10% DMSO were injected. Clinical
symptoms of arthritis were different in the group treated with the Vitis vinifera pip extract and the group not treated with the Vitis vinifera pip extract (FIG. 10).
A joint piece was dyed with hematoxylin and eosin in the same manner as in (2-2) of Experimental Example 1 , and the results are shown in FIG. 11. As a result of the histological test, a number of immune cells were infiltrated in joints of the animals into which saline and 10% DMSO were injected, and pannus formation, destruction of cartilage, and bone infiltration were observed. On the other hand, the degree of destruction of joint and cartilage in the mice into which the Vitis vinifera pip extract and celecoxib were injected was similar to that of a normal mouse (FIG. 11). A serologic test was conducted in the same manner as in (2-3) of Experimental
Example 1 , and the results are shown in FIGS. 12 and 13. Serum of each of the test groups was diluted in a ratio 1 :8000, and subtype of Total IgG antibody was measured. Th2 type IgGI was not changed (FIG. 12), but Th1 type Cll-specific lgG2a was decreased in the animals into which the Vitis vinifera pip extract was injected compared with the animals into which saline was injected (FIG. 13).
3. Evaluation of regulation of cytokine by Vitis vinifera pip extract The amount of IL-17, TNF alpha, and IL-1β was measured in the same manner as in 3 of Experimental Example 1. As a result, the amount of IL-17, TNF alpha2, and IL-1β was significantly decreased in the group into which the Vitis vinifera pip extract was administered compared with the group into which saline was administered (FIGS. 14 to 16).
Claims
1. A process for preparing a Vitis vinifera pip extract, the process comprising:
(a) extracting pulverized seeds of Vitis vinifera at room temperature with a mixed solvent of acetone and water in a volume ratio of 1 : 1-2, and then filtering the resultant;
(b) distilling the filtrate prepared in step (a) to remove acetone, saturating with sodium chloride, and then filtering the resultant;
(c) extracting the filtrate prepared in step (b) with ethyl acetate, and then concentrating the resultant; and (d) adding chloroform to the concentrate prepared in step (c), and then precipitating the resultant by filtration.
2. The process of claim 1 , wherein the volume ratio of acetone and water in the mixed solvent of step (a) is 1 : 1.5.
3. The process of claim 1 , wherein the extraction of steps (a) and (c) is repeated 2 to 3 times.
4. The process of claim 1 , wherein the distillation of step (b) is conducted at 500C or less under a reduced pressure.
5. The process of claim 1 , wherein the filtering of step (b) is conducted after standing for 2 to 3 hours from the saturation with sodium chloride.
6. The process of claim 1 , wherein the concentrating in step (c) is conducted to a volume of 0.4 to 0.7 times of the total volume of the extract.
7. A process for preparing a Vitis vinifera pip extract, the process comprising:
(A) preparing a first extract by (i) extracting pulverized seeds of Vitis vinifera with a mixed solvent of acetone and water in a volume ratio of 3-5 : 1 , and then filtering the resultant; (ii) concentrating the filtrate prepared in step (i) to remove acetone, and then filtering the resultant; (iii) extracting the filtrate prepared in step (ii) with ethyl acetate; and (iv) drying the extract prepared in step (iii);
(B) preparing a second extract by (p) extracting pulverized seeds of Vitis vinifera with water, and the filtering the resultant; (q) extracting the filtrate prepared in step (p) with ethanol, and then filtering the resultant; and (r) drying the filtrate prepared in step (q); and
(C) mixing the first extract and the second extract.
8. The process of claim 7, wherein the volume ratio of acetone and water in the mixed solution of step (i) is 4 : 1
9. The process of claim 7, wherein the extraction of step (iii) or (q) is repeated 2 to 3 times.
10. The process of claim 7, further comprising dehydrating the resulting extract in step (iii).
11. The process of claim 7, wherein the drying of step (iv) is conducted by concentrating the extract prepared in step (iii) to remove ethyl acetate, dissolving the concentrate in water, and then spray-drying the resultant.
12. The process of claim 7, wherein the drying of step (r) is conducted by spray-drying the filtrate prepared in step (q).
13. The process of claim 7, wherein the drying of step (r) is conducted by concentrating the filtrate prepared in step (q), and then spray-drying the concentrate.
14. The process of claim 7, wherein the mixing ratio of the first extract and the second extract is 1 : 0.5-1.5 by weight.
15. The process according to any one of claims 1 to 14, wherein the obtained Vitis vinifera pip extract has 80-130% of Procyanidolic value (PCV); 30% or less of (+)catechin and (-)epicatechin; and 95-105% of proanthocyanidin.
16. A pharmaceutical composition for preventing or treating rheumatoid arthritis comprising a Vitis vinifera pip extract as an active ingredient and a pharmaceutically acceptable carrier.
17. The pharmaceutical composition of claim 16, wherein the Vitis vinifera pip extract is obtained by a process comprising:
(a) extracting pulverized seeds of Vitis vinifera at room temperature with a mixed solvent of acetone and water in a volume ratio of 1 : 1-2, and then filtering the resultant;
(b) distilling the filtrate prepared in step (a) to remove acetone, saturating with sodium chloride, and then filtering the resultant; (c) extracting the filtrate prepared in step (b) with ethyl acetate, and then concentrating the resultant; and
(d) adding chloroform to the concentrate prepared in step (c), and then precipitating the resultant by filtration.
18. The pharmaceutical composition of claim 17, wherein the volume ratio of acetone and water in the mixed solvent of step (a) is 1 : 1.5.
19. The pharmaceutical composition of claim 17, wherein the extraction of steps (a) and (c) is repeated 2 to 3 times.
20. The pharmaceutical composition of claim 17, wherein the distillation of step (b) is conducted at 500C or less under a reduced pressure.
21. The pharmaceutical composition of claim 17, wherein the filtering of step (b) is conducted after standing for 2 to 3 hours from the saturation with sodium chloride.
22. The pharmaceutical composition of claim 17, wherein the concentrating in step (c) is conducted to a volume of 0.4 to 0.7 times of the total volume of the extract.
23. The pharmaceutical composition of claim 16, wherein the Vitis vinifera pip extract is obtained by a process comprising:
(1) preparing a first extract by (i) extracting pulverized seeds of Vitis vinifera with a mixed solvent of acetone and water in a volume ratio of 3-5 : 1 , and then filtering the resultant; (ii) concentrating the filtrate prepared in step (i) to remove acetone, and then filtering the resultant; (iii) extracting the filtrate prepared in step (ii) with ethyl acetate; and (iv) drying the extract prepared in step (iii);
(2) preparing a second extract by (p) extracting pulverized seeds of Vitis vinifera with water, and the filtering the resultant; (q) extracting the filtrate prepared in step (p) with ethanol, and then filtering the resultant; and (r) drying the filtrate prepared in step (q); and (3) mixing the first extract and the second extract.
24. The pharmaceutical composition of claim 23, wherein the volume ratio of acetone and water in the mixed solution of step (i) is 4 : 1
25. The pharmaceutical composition of claim 23, wherein the extraction of step (iii) or (q) is repeated 2 to 3 times.
26. The pharmaceutical composition of claim 23, further comprising dehydrating the resulting extract in step (iii)
27. The pharmaceutical composition of claim 23, wherein the drying of step (iv) is conducted by concentrating the extract prepared in step (iii) to remove ethyl acetate, dissolving the concentrate in water, and then spray-drying the resultant.
28. The pharmaceutical composition of claim 23, wherein the drying of step (r) is conducted by spray-drying the filtrate prepared in step (q).
29. The pharmaceutical composition of claim 23, wherein the drying of step (r) is conducted by concentrating the filtrate prepared in step (q), and then spray-drying the concentrate.
30. The pharmaceutical composition of claim 23, wherein the mixing ratio of the first extract and the second extract is 1 : 0.5-1.5 by weight.
31. The pharmaceutical composition according to any one of claims 16 to 30, wherein the Vitis vinifera pip extract has 80-130% of Procyanidolic value (PCV); 30% or less of (+)catechin and (-)epicatechin; and 95-105% of proanthocyanidin.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/733,461 US20100173028A1 (en) | 2007-09-04 | 2008-09-04 | Process for preparing vitis vinifera pip extract and pharmaceutical composition for preventing or treating rheumatoid arthritis comprising the same |
| EP08793681A EP2182967A1 (en) | 2007-09-04 | 2008-09-04 | Process for preparing vitis vinifera pip extract and pharmaceutical composition for preventing or treating rheumatoid arthritis comprising the same |
| CN2008801055362A CN102006880A (en) | 2007-09-04 | 2008-09-04 | Process for preparing vitis vinifera pip extract and pharmaceutical composition for preventing or treating rheumatoid arthritis comprising the same |
| JP2010523948A JP2010538058A (en) | 2007-09-04 | 2008-09-04 | Method for preparing seed extract of bitis vinifera and pharmaceutical composition for prevention or treatment of rheumatoid arthritis containing the extract |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20070089273 | 2007-09-04 | ||
| KR10-2007-0089273 | 2007-09-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2009031826A1 true WO2009031826A1 (en) | 2009-03-12 |
Family
ID=40429066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2008/005203 WO2009031826A1 (en) | 2007-09-04 | 2008-09-04 | Process for preparing vitis vinifera pip extract and pharmaceutical composition for preventing or treating rheumatoid arthritis comprising the same |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20100173028A1 (en) |
| EP (1) | EP2182967A1 (en) |
| JP (1) | JP2010538058A (en) |
| KR (2) | KR101044433B1 (en) |
| CN (1) | CN102006880A (en) |
| WO (1) | WO2009031826A1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101044433B1 (en) | 2007-09-04 | 2011-06-27 | 에이치 엘 지노믹스(주) | Process for preparing Vitis vinifera pip extract and pharmaceutical composition for preventing or treating rheumatoid arthritis comprising the same |
| JPWO2011004734A1 (en) * | 2009-07-08 | 2012-12-20 | アークレイ株式会社 | Carboxymethylarginine production inhibitor and collagen denaturation inhibitor |
| CN112043822A (en) * | 2020-09-25 | 2020-12-08 | 福建省春秋刺明珠葡萄酒庄园有限公司 | Vitis davidii plant extract preparation rich in anthocyanin and preparation method thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101099021B1 (en) * | 2009-04-24 | 2011-12-28 | 에이치 엘 지노믹스(주) | Pharmaceutical composition for preventing or treating osteoarthritis comprising Vitis vinifera pip extract |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1541469A (en) | 1976-12-01 | 1979-02-28 | Inverni Della Beffa Spa | Method of obtaining flavonolic oligomers |
| WO2005002611A1 (en) * | 2003-06-27 | 2005-01-13 | Indena S.P.A. | Formulations for the treatment of arhritis conditions |
| KR20060110018A (en) * | 2005-04-04 | 2006-10-24 | 중모포도영농조합법인 | A preparation methods of grape seed oil and extract with high quality |
| US20070134354A1 (en) * | 2003-10-08 | 2007-06-14 | Biosistema S.R.L. | Process for producing a grape seed extract having a low content of monomeric polyphenols |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1201151B (en) * | 1987-01-14 | 1989-01-27 | Indena Spa | PHOSPHOLIPID COMPLEXES WITH EXTRACTS FROM VITIS VINIFERA, PROCEDURE FOR THEIR PREPARATION AND COMPOSITIONS THAT CONTAIN THEM |
| US5484594A (en) * | 1988-06-28 | 1996-01-16 | Tecnofarmaci S.P.A. | Process for preparing grapeseed extracts enriched in procyanidol oligomers |
| FR2808190B1 (en) * | 2000-04-28 | 2002-06-21 | Oreal | PLANT EXTRACT OF THE SPECIES VITIS VINIFERA AS NO-SYNTHASE INHIBITOR AND USES |
| US20060105989A1 (en) | 2004-11-18 | 2006-05-18 | Kinya Takagaki | Food for improving arthritis |
| US8318973B2 (en) * | 2005-10-21 | 2012-11-27 | Bezwada Biomedical, Llc | Functionalized sinapic acid and methyl sinapate |
| WO2009031826A1 (en) | 2007-09-04 | 2009-03-12 | Catholic University Industry Academic Cooperation Foundation | Process for preparing vitis vinifera pip extract and pharmaceutical composition for preventing or treating rheumatoid arthritis comprising the same |
-
2008
- 2008-09-04 WO PCT/KR2008/005203 patent/WO2009031826A1/en active Application Filing
- 2008-09-04 CN CN2008801055362A patent/CN102006880A/en active Pending
- 2008-09-04 US US12/733,461 patent/US20100173028A1/en not_active Abandoned
- 2008-09-04 EP EP08793681A patent/EP2182967A1/en not_active Withdrawn
- 2008-09-04 KR KR1020080087109A patent/KR101044433B1/en active IP Right Grant
- 2008-09-04 JP JP2010523948A patent/JP2010538058A/en active Pending
-
2011
- 2011-03-09 KR KR1020110020720A patent/KR101399925B1/en active IP Right Grant
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1541469A (en) | 1976-12-01 | 1979-02-28 | Inverni Della Beffa Spa | Method of obtaining flavonolic oligomers |
| WO2005002611A1 (en) * | 2003-06-27 | 2005-01-13 | Indena S.P.A. | Formulations for the treatment of arhritis conditions |
| US20070134354A1 (en) * | 2003-10-08 | 2007-06-14 | Biosistema S.R.L. | Process for producing a grape seed extract having a low content of monomeric polyphenols |
| KR20060110018A (en) * | 2005-04-04 | 2006-10-24 | 중모포도영농조합법인 | A preparation methods of grape seed oil and extract with high quality |
Non-Patent Citations (1)
| Title |
|---|
| MIN,HYE-YOUNG ET AL.: "Effects of grape extract on free radical scavenging acitivity and inhibition of pro-inflammatory mediator production in mouse macrophage cells", KOREAN J. FOOD SCI.TECHNOL., vol. 35, no. 1, 2003, pages 132 - 137 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101044433B1 (en) | 2007-09-04 | 2011-06-27 | 에이치 엘 지노믹스(주) | Process for preparing Vitis vinifera pip extract and pharmaceutical composition for preventing or treating rheumatoid arthritis comprising the same |
| JPWO2011004734A1 (en) * | 2009-07-08 | 2012-12-20 | アークレイ株式会社 | Carboxymethylarginine production inhibitor and collagen denaturation inhibitor |
| CN112043822A (en) * | 2020-09-25 | 2020-12-08 | 福建省春秋刺明珠葡萄酒庄园有限公司 | Vitis davidii plant extract preparation rich in anthocyanin and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102006880A (en) | 2011-04-06 |
| JP2010538058A (en) | 2010-12-09 |
| KR101044433B1 (en) | 2011-06-27 |
| KR20090024647A (en) | 2009-03-09 |
| KR101399925B1 (en) | 2014-05-29 |
| EP2182967A1 (en) | 2010-05-12 |
| US20100173028A1 (en) | 2010-07-08 |
| KR20110036031A (en) | 2011-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shin et al. | Preventive effects of skullcap (Scutellaria baicalensis) extract in a mouse model of food allergy | |
| KR20040074614A (en) | Medicinal preparation containing phenylethanoid glycosides extracted from herbaceous plant, cistanche tubulosa(schenk.)wight, process of making the same, and uses of the same | |
| JP2009542634A (en) | Pharmaceutical composition for the prevention and treatment of inflammatory diseases comprising extract | |
| US8945633B2 (en) | Pharmaceutical composition for preventing and treating inflammatory diseases containing an ethyl acetate fraction of dried extract of Trachelospermi caulis as an active ingredient, and method for producing the fraction | |
| US20100173028A1 (en) | Process for preparing vitis vinifera pip extract and pharmaceutical composition for preventing or treating rheumatoid arthritis comprising the same | |
| CN111067949A (en) | Potentilla tormentosa total flavone effective part with lipopexia inhibiting effect, and preparation method and application thereof | |
| CN104739917B (en) | The purposes of plant extract and preparation treatment hepatic fibrosis-renal tubular ectasia syndrome and the drug of liver cancer | |
| CN106491680B (en) | A Chinese medicinal composition for preventing or treating senile dementia, and its preparation method | |
| JP5267885B2 (en) | Pharmaceutical composition for prevention and / or treatment of inflammatory diseases, comprising a mixed extract of Tsukiishi wisteria and Ichiyakuso | |
| Vetrichelvan et al. | Effect of alcoholic extract of Achyranthes bidentata blume on acute and sub acute inflammation | |
| JP2000503686A (en) | Pharmaceutical composition for the treatment of hepatitis C, comprising a mixed extract of yellow bamboo skin and Ominaeushi plant | |
| JP5984853B2 (en) | Extract of Java silicate, extraction method and use thereof as proton pump down regulator, enzyme inhibitor and mucosal protective agent | |
| KR101250181B1 (en) | composition for preventing and curing osteoporosis comprising two terpenoids, fraction or extract from Euphorbia kansui | |
| CN113244281B (en) | Application of Huangshui Zhitong extract in preparing medicine for treating, protecting and regulating liver fibrosis diseases | |
| CN108514568A (en) | The preparation method and its medical usage of thiazides compounds in the achene of Siberian cocklebur | |
| KR101096574B1 (en) | Pharmaceutical composition for preventing or treating osteoporosis comprising Vitis vinifera pip extract | |
| CN112076235A (en) | Application of rhus chinensis fruit in preparation of medicine for treating or preventing hepatic fibrosis | |
| KR20080101344A (en) | Composition for the anti-inflammatory and analgesia comprising tannin-contained kalopanacis cortex extract | |
| KR20110137588A (en) | Pharmaceutical composition for preventing or treating obesity comprising vitis vinifera pip extract | |
| KR100816854B1 (en) | Compositions for preventing and treating allergy comprising phellinus baumii | |
| KR20070088984A (en) | Araliaceae extracts compositions for treating or preventing inflammatory diseases | |
| CN117899131A (en) | Lygodium japonicum extract and preparation method and application thereof | |
| CN1961911A (en) | Lyophilized powder injection containing red sage root and dalbergia wood volatile oil and preparation method thereof | |
| KR960000242A (en) | Radix extract inhibiting the production of interleukin-6 and its preparation method | |
| KR20230052732A (en) | Health functional food composition extracted by supercritical extraction method with_mixing propolis of different origins for improving immune function and manufacturing method therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 200880105536.2 Country of ref document: CN |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08793681 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2008793681 Country of ref document: EP |
|
| ENP | Entry into the national phase |
Ref document number: 2010523948 Country of ref document: JP Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 12733461 Country of ref document: US Ref document number: 414/MUMNP/2010 Country of ref document: IN |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |